Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
PDS Biotechnology Corp (EDGE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Condensed Consolidated Balance Sheets"
05/15/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/31/2022 8-K Quarterly results
Docs: "FLORHAM PARK, N.J., March 31, 2022 -- PDS Biotechnology Corporation , a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™ T-cell activating technologies, today provided a business update and announced its financial results for the year ended December 31, 2021. “I’m very pleased to report that we have undergone a 12-month period of incredible productivity here at PDS Biotech,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of the Company. “We’ve made significant clinical progress on our lead oncology candidate, PDS0101, and presented at leading oncology conferences on the promising efficacy and safety resu..."
11/10/2021 8-K Quarterly results
Docs: "PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results FLORHAM PARK, N.J., November 10, 2021",
"PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute",
"Updated Corporate Presentation November 2021"
03/18/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update",
"PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck",
"PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine"
08/13/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
03/27/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update"
08/01/2019 8-K Quarterly results
Docs: "PDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update"
05/14/2019 8-K Quarterly results
Docs: "PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update"
11/01/2018 8-K Quarterly results
Docs: "BERKELEY HEIGHTS, N.J., November 1, 2018"
08/01/2018 8-K Quarterly results
Docs: "BERKELEY HEIGHTS, N.J., August 1, 2018"
05/01/2018 8-K Quarterly results
Docs: "BERKELEY HEIGHTS, N.J., May 1, 2018"
11/01/2017 8-K Quarterly results
Docs: "Executive Employment Agreement by and between Andrew Saik and Edge entered into as of October 31, 2017",
"BERKELEY HEIGHTS, N.J., November 1, 2017 — Edge Therapeutics ® , Inc. , a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial and operational results for the quarter ended September 30, 2017, and recent corporate progress. Third Quarter and Recent Corporate Progress"
08/01/2017 8-K Quarterly results
Docs: "BERKELEY HEIGHTS, N.J., August 1, 2017 — Edge Therapeutics, Inc. , a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial and operational results for the quarter ended June 30, 2017, and recent corporate progress."
05/03/2017 8-K Form 8-K - Current report
11/01/2016 8-K Quarterly results
Docs: "BERKELEY HEIGHTS, N.J., November 1, 2016 — Edge Therapeutics, Inc. , a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial results for the three months ended September 30, 2016 and recent highlights."
08/03/2016 8-K Form 8-K - Current report
05/03/2016 8-K Form 8-K - Current report
03/08/2016 8-K Quarterly results
Docs: "BERKELEY HEIGHTS, N.J. –"
11/06/2015 8-K Quarterly results
Docs: "Edge Therapeutics Reports Third Quarter 2015 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy